International Assets Investment Management LLC Takes Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

International Assets Investment Management LLC bought a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 13,916 shares of the company’s stock, valued at approximately $8,610,000.

A number of other institutional investors have also added to or reduced their stakes in AMPH. McGlone Suttner Wealth Management Inc. bought a new position in shares of Amphastar Pharmaceuticals in the 4th quarter valued at about $28,000. China Universal Asset Management Co. Ltd. increased its position in Amphastar Pharmaceuticals by 99.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,261 shares of the company’s stock worth $58,000 after buying an additional 628 shares during the period. Covestor Ltd lifted its holdings in shares of Amphastar Pharmaceuticals by 859.0% during the third quarter. Covestor Ltd now owns 1,966 shares of the company’s stock worth $90,000 after buying an additional 1,761 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Amphastar Pharmaceuticals by 115.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,430 shares of the company’s stock valued at $150,000 after acquiring an additional 1,300 shares during the period. Finally, Annex Advisory Services LLC acquired a new position in shares of Amphastar Pharmaceuticals in the third quarter valued at about $204,000. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Stock Performance

NASDAQ AMPH opened at $42.68 on Tuesday. Amphastar Pharmaceuticals, Inc. has a 1 year low of $36.06 and a 1 year high of $67.66. The firm has a market capitalization of $2.05 billion, a price-to-earnings ratio of 16.54, a P/E/G ratio of 1.02 and a beta of 0.85. The company has a current ratio of 2.17, a quick ratio of 1.70 and a debt-to-equity ratio of 0.92. The firm’s 50 day simple moving average is $43.23 and its 200 day simple moving average is $50.76.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its earnings results on Wednesday, February 28th. The company reported $0.81 earnings per share for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.03). The company had revenue of $178.11 million during the quarter, compared to analyst estimates of $174.90 million. Amphastar Pharmaceuticals had a net margin of 21.34% and a return on equity of 26.95%. As a group, research analysts expect that Amphastar Pharmaceuticals, Inc. will post 3.41 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Amphastar Pharmaceuticals news, Director Michael A. Zasloff sold 12,500 shares of the stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $47.18, for a total value of $589,750.00. Following the completion of the transaction, the director now directly owns 21,326 shares in the company, valued at $1,006,160.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 14,000 shares of company stock worth $655,145 in the last 90 days. Insiders own 27.10% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. JPMorgan Chase & Co. assumed coverage on shares of Amphastar Pharmaceuticals in a research note on Tuesday, March 5th. They issued an “overweight” rating and a $60.00 price objective for the company. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, April 10th. Finally, StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $66.00.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.